In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Biomarker correlates of coronary microvascular dysfunction and diastolic dysfunction in heart failure with preserved ejection fraction

Session Rapid Fire 2 - Biomarker: present and future

Speaker Jasper Tromp

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Heart Failure with Preserved Ejection Fraction
  • Session type : Rapid Fire Abstracts
  • FP Number : 62

Authors : J Tromp (Singapore,SG), C Hage (Stockholm,SE), S Sanders-Van Wijk (Maastricht,NL), S Svedlund (Gothenburg,SE), A Saraste (Turku,FI), UL Faxen (Stockholm,SE), M Lagerstrom Fermer (Gothenburg,SE), LM Gan (Gothenburg,SE), LH Lund (Stockholm,SE), SJ Shah (Chicago,US), CSP Lam (Singapore,SG)

Authors:
J Tromp1 , C Hage2 , S Sanders-Van Wijk3 , S Svedlund4 , A Saraste5 , UL Faxen2 , M Lagerstrom Fermer6 , LM Gan4 , LH Lund2 , SJ Shah7 , CSP Lam1 , 1National Heart Centre Singapore, Cardiology - Singapore - Singapore , 2Karolinska Institute - Stockholm - Sweden , 3Cardiovascular Research Institute Maastricht (CARIM) - Maastricht - Netherlands (The) , 4University of Gothenburg - Gothenburg - Sweden , 5Turku University Hospital - Turku - Finland , 6AstraZeneca - Gothenburg - Sweden , 7Northwestern University - Chicago - United States of America ,

Citation:

Background. Limited data is available on the pathophysiological mechanisms and the role of underlying coronary microvascular (CMD) in heart failure with preserved ejection fraction (HFpEF). Therefore, we studied biomarker profiles associated with CMD and associations between left ventricular systolic and diastolic dysfunction and structural derangements in HFpEF.

Methods. We measured 268 biomarkers from different pathophysiological domains (e.g. inflammation, oxidative stress) in 192 patients with stable HFpEF from the prospective PROMIS-HFpEF study. Coronary flow reserve (CFR) was measured with adenosine stress transthoracic Doppler echocardiography. Elastic net regression analyses combined with network and pathway overrepresentation analyses were used to identify key pathophysiological biomarkers and mechanisms associated with CFR as well as global longitudinal strain (GLS), lateral E’ and left atrial volume indexed to body surface area (LAVi).

Results. In total, 11 biomarkers were significantly associated with CFR with the strongest predictors being N-terminal pro B-type natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF15), insulin-like growth factor binding protein 1 (IGFBP1) and surfactant protein D (PSPD). Only NT-proBNP was significantly associated with both CFR, LAVi, lateral E’ and GLS (P <0.001 for all). Network analyses showed that Pappalysin-1 (PAPPA) was an important hub (Figure A). Insulin-like growth factor receptor pathways and T-cell migration were most strongly associated with CFR (Figure B) in pathway overrepresentation analyses.

Conclusions. In HFpEF, CMD is associated with a unique biomarker profile, related to T-cell migration and insulin-like growth factor receptor signaling. These data highlight IGF signaling and immune cell trafficking as distinct pathophysiological correlates of CMD in HFpEF



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are